Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides - PubMed (original) (raw)
Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
F C Tenover et al. J Clin Microbiol. 1998 Apr.
Erratum in
- J Clin Microbiol 1998 Jul;36(7):2167
Abstract
During the last several years a series of staphylococcal isolates that demonstrated reduced susceptibility to vancomycin or other glycopeptides have been reported. We selected 12 isolates of staphylococci for which the vancomycin MICs were > or =4 microg/ml or for which the teicoplanin MICs were > or =8 microg/ml and 24 control strains for which the vancomycin MICs were < or =2 microg/ml or for which the teicoplanin MICs were < or =4 microg/ml to determine the ability of commercial susceptibility testing procedures and vancomycin agar screening methods to detect isolates with reduced glycopeptide susceptibility. By PCR analysis, none of the isolates with decreased glycopeptide susceptibility contained known vancomycin resistance genes. Broth microdilution tests held a full 24 h were best at detecting strains with reduced glycopeptide susceptibility. Disk diffusion did not differentiate the strains inhibited by 8 microg of vancomycin per ml from more susceptible isolates. Most of the isolates with reduced glycopeptide susceptibility were recognized by MicroScan conventional panels and Etest vancomycin strips. Sensititre panels read visually were more variable, although with some of the panels MICs of 8 microg/ml were noted for these isolates. Vitek results were 4 microg/ml for all strains for which the vancomycin MICs were > or =4 microg/ml. Vancomycin MICs on Rapid MicroScan panels were not predictive, giving MICs of either < or =2 or > or =16 microg/ml for these isolates. Commercial brain heart infusion vancomycin agar screening plates containing 6 microg of vancomycin per ml consistently differentiated those strains inhibited by 8 microg/ml from more susceptible strains. Vancomycin-containing media prepared in-house showed occasional growth of susceptible strains, Staphylococcus aureus ATCC 29213, and on occasion, Enterococcus faecalis ATCC 29212. Thus, strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h. Furthermore, it appears that commercial vancomycin agar screening plates can be used to detect these isolates.
Figures
FIG. 1
Distribution of disk diffusion zone diameters of Staphylococcus species obtained with a 30-μg vancomycin disk or a 30-μg teicoplanin disk. Discrepant results are (a) an S. epidermidis (GSSS) isolate for which the teicoplanin zone diameter was 13 mm and the teicoplanin MIC was 4 μg/ml, (b) an S. epidermidis (GSSS) isolate for which the teicoplanin zone diameter was 15 mm and the teicoplanin MIC was 4 μg/ml, and (c) an S. aureus (GISA) isolate (isolate N20) for which the teicoplanin zone diameter was 17 mm and the teicoplanin MIC was 1 μg/ml.
FIG. 2
PFGE patterns of _Sma_I-digested DNA from S. aureus isolates exhibiting reduced susceptibility to vancomycin. ATCC, S. aureus ATCC 29213; Std, molecular size standard.
Similar articles
- Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME, Gesu G, Ortisi G, Sahm DF, Critchley IA, Goglio A; Associazione Microbiologi Clinici Italiani (AMCLI) Committee for Antibiotics. Jones ME, et al. Clin Microbiol Infect. 2002 Feb;8(2):101-11. doi: 10.1046/j.1469-0691.2002.00378.x. Clin Microbiol Infect. 2002. PMID: 11952723 - Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP. Vaudaux P, et al. Antimicrob Agents Chemother. 2010 Sep;54(9):3861-70. doi: 10.1128/AAC.00269-10. Epub 2010 Jun 14. Antimicrob Agents Chemother. 2010. PMID: 20547791 Free PMC article. - Susceptibility of Brazilian staphylococcal strains to glycopeptides evaluated by different testing methods.
Ferreira Nunes AP, Martins Teixeira L, Reis Bastos CC, de Souza Fonseca L, Netto dos Santos KR. Ferreira Nunes AP, et al. Curr Microbiol. 2002 Jun;44(6):385-90. doi: 10.1007/s00284-001-0027-3. Curr Microbiol. 2002. PMID: 12000986 - Glycopeptide resistance in coagulase-negative staphylococci.
Biavasco F, Vignaroli C, Varaldo PE. Biavasco F, et al. Eur J Clin Microbiol Infect Dis. 2000 Jun;19(6):403-17. doi: 10.1007/s100960000299. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10947214 Review. - Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.
Tenover FC, Biddle JW, Lancaster MV. Tenover FC, et al. Emerg Infect Dis. 2001 Mar-Apr;7(2):327-32. doi: 10.3201/eid0702.010237. Emerg Infect Dis. 2001. PMID: 11294734 Free PMC article. Review.
Cited by
- Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
Vaudaux P, Ferry T, Uçkay I, François P, Schrenzel J, Harbarth S, Renzoni A. Vaudaux P, et al. Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3367-74. doi: 10.1007/s10096-012-1705-8. Epub 2012 Jul 26. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22833247 - A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
Wootton M, MacGowan AP, Walsh TR, Howe RA. Wootton M, et al. J Clin Microbiol. 2007 Feb;45(2):329-32. doi: 10.1128/JCM.01508-06. Epub 2006 Nov 15. J Clin Microbiol. 2007. PMID: 17108069 Free PMC article. - Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers.
Scherl A, François P, Charbonnier Y, Deshusses JM, Koessler T, Huyghe A, Bento M, Stahl-Zeng J, Fischer A, Masselot A, Vaezzadeh A, Gallé F, Renzoni A, Vaudaux P, Lew D, Zimmermann-Ivol CG, Binz PA, Sanchez JC, Hochstrasser DF, Schrenzel J. Scherl A, et al. BMC Genomics. 2006 Nov 22;7:296. doi: 10.1186/1471-2164-7-296. BMC Genomics. 2006. PMID: 17121677 Free PMC article. - First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, Hiramatsu K. Trakulsomboon S, et al. J Clin Microbiol. 2001 Feb;39(2):591-5. doi: 10.1128/JCM.39.2.591-595.2001. J Clin Microbiol. 2001. PMID: 11158112 Free PMC article. - Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Pitz AM, et al. J Clin Microbiol. 2011 Jan;49(1):269-74. doi: 10.1128/JCM.00914-10. Epub 2010 Oct 20. J Clin Microbiol. 2011. PMID: 20962147 Free PMC article.
References
- Aarestrup F M, Ahrens P, Madsen M, Pallesen L V, Poulsen R L, Westh H. Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster. Antimicrob Agents Chemother. 1996;40:1938–1940. - PMC - PubMed
- AB Biodisk America Inc. Etest package insert. Piscataway, N.J: AB Biodisk North America Inc.; 1996.
- Archer G L, Auger P, Doern G V, Ferraro M J, Fuchs P C, Jorgensen J H, Low D E, Murray P R, Reller L B, Stratton C W, Wennersten C B, Moellering R C., Jr RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis. 1993;16:223–226. - PubMed
- Barna J C, Williams D H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 1984;38:339–357. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical